Dipyridamole decreases dialysis risk and improves survival in patients with pre-dialysis advanced chronic kidney disease.

ABSTRACT:

Introduction

Dipyridamole decreases proteinuria and improves renal function progression in patients with glomerular disease through its inhibition of platelet activation and enhanced nitric oxide expression. Few studies have evaluated the effects of dipyridamole on renal outcome or survival in CKD stage 5 patients who have not yet received dialysis (CKD 5 ND).

Materials and methods

A prospective cohort study was conducted based on the Taiwan National Health Insurance Research Database. From January 1, 2000 to June 30, 2009, we enrolled 28,497 patients who had a serum creatinine > 6 mg/dL and a hematocrit < 28% and who were treated with erythropoiesis-stimulating agents (ESAs). All patients were further divided into two groups with or without dipyridamole use within 90 days a

SUBMITTER: Kuo KL 

PROVIDER: S-EPMC5797055 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature